Evolent Health Inc
For the period ended Dec 31, 2024. Filed Feb 21, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 21, 2025
EVH$4.80+1.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Changes in Mezzanine and Shareholders’ Equity
| EVOLENT HEALTH, INC. | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| CONSOLIDATED STATEMENTS OF CHANGES IN MEZZANINE AND SHAREHOLDERS’ EQUITY | |||||||||
| (in thousands) | |||||||||
| Mezzanine Equity · Shareholders’ Equity | |||||||||
| Series A Preferred Stock · Class A Common Stock · Additional Paid-In Capital · Accumulated Other Comprehensive Loss · Retained Earnings (Accumulated Deficit) · Treasury Stock · Total Shareholders' Equity | |||||||||
| Shares · Amount · Shares · Amount | |||||||||
| Balance as of December 31, 2021 | — | $— | 90,759 | $908 | $1,340,989 | $(362) | $(626,779) | $(21,123) | $693,633 |
| Cumulative-effect adjustment from adoption of ASC 2020-06 | — | — | — | — | (106,172) | — | 39,789 | — | (66,383) |
| Stock-based compensation expense | — | — | — | — | 33,981 | — | — | — | 33,981 |
| Exercise of stock options | — | — | 651 | 6 | 4,446 | — | — | — | 4,452 |
| Restricted stock units vested, net of shares withheld for taxes | — | — | 496 | 5 | (7,091) | — | — | — | (7,086) |
| Leveraged stock units vested, net of shares withheld for taxes | — | — | 459 | 5 | (11,237) | — | — | — | (11,232) |
| Exchange of 2024 Notes | — | — | 5,394 | 54 | 101,803 | — | — | — | 101,857 |
| Shares issued for acquisition | — | — | 3,742 | 37 | 130,138 | — | — | — | 130,175 |
| Foreign currency translation adjustment | — | — | — | — | — | (816) | — | — | (816) |
| Net loss attributable to common shareholders of Evolent Health, Inc. | — | — | — | — | — | — | (19,164) | — | (19,164) |
| Balance as of December 31, 2022 | — | — | 101,501 | 1,015 | 1,486,857 | (1,178) | (606,154) | (21,123) | 859,417 |
| Stock-based compensation expense | — | — | — | — | 40,501 | — | — | — | 40,501 |
| Exercise of stock options | — | — | 1,406 | 14 | 12,505 | — | — | — | 12,519 |
| Restricted stock units vested, net of shares withheld for taxes | — | — | 630 | 6 | (11,323) | — | — | — | (11,317) |
| Performance stock units vested, net of shares withheld for taxes | — | — | 202 | 2 | (3,977) | — | — | — | (3,975) |
| Leveraged stock units vested, net of shares withheld for taxes | — | — | 1,040 | 10 | (10) | — | — | — | — |
| 2024 Note conversion | — | — | 1,294 | 13 | 23,060 | — | — | — | 23,073 |
| Shares issued for acquisition | — | — | 8,475 | 85 | 261,186 | — | — | — | 261,271 |
| Class A common stock issued for payments of earn-outs | — | — | 877 | 9 | 28,542 | — | — | — | 28,551 |
| Issuance of series A preferred stock, net of issuance costs | 175 | 168,000 | — | — | — | — | — | — | — |
| Foreign currency translation adjustment | — | — | — | — | — | (79) | — | — | (79) |
| Net loss attributable to common shareholders of Evolent Health, Inc. | — | 10,427 | — | — | (29,220) | — | (113,040) | — | (142,260) |
| Balance as of December 31, 2023 | 175 | 178,427 | 115,425 | 1,154 | 1,808,121 | (1,257) | (719,194) | (21,123) | 1,067,701 |
| Stock-based compensation expense | — | — | — | — | 39,746 | — | — | — | 39,746 |
| Exercise of stock options | — | — | 335 | 4 | 3,457 | — | — | — | 3,461 |
| Restricted stock units vested, net of shares withheld for taxes | — | — | 611 | 6 | (11,141) | — | — | — | (11,135) |
| Performance stock units vested, net of shares withheld for taxes | — | — | 205 | 2 | (4,566) | — | — | — | (4,564) |
| Foreign currency translation adjustment | — | — | — | — | — | (496) | — | — | (496) |
| Net loss attributable to common shareholders of Evolent Health, Inc. | — | 11,746 | — | — | (31,831) | — | (61,623) | — | (93,454) |
| Balance as of December 31, 2024 | 175 | $190,173 | 116,576 | $1,166 | $1,803,786 | $(1,753) | $(780,817) | $(21,123) | $1,001,259 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.